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Abstract 
Accelerated atherosclerosis is the main underlying factor contributing to the high risk of atherothrombotic events in 
patients with diabetes mellitus and atherothrombotic complications are the main cause of mortality. Like with many 
bodily systems, pathology is observed when the normal processes are exaggerated or uncontrolled. This applies to 
the processes of coagulation and thrombosis as well. In diabetes, in fact, the balance between prothrombotic and 
fibrinolytic factors is impaired and thus the scale is tipped towards a prothrombotic and hypofibrinolytic milieu, which 
in association with the vascular changes accompanying plaque formation and ruptures, increases the prevalence of 
ischaemic events such as angina and myocardial infarction. Apart from traditional, modifiable risk factors for cardio-
vascular disease like hypertension, smoking, elevated cholesterol; rheological properties, endogenous fibrinolysis and 
impaired platelet activity are rapidly gaining significance in the pathogenesis of atherosclerosis especially in diabetic 
subjects. Blood clot formation represents the last step in the athero-thrombotic process, and the structure of the fibrin 
network has a role in determining predisposition to cardiovascular disease. It is no surprise that just like platelets and 
fibrin networks, erythrocytes have been shown to play a role in coagulation as well. This is in striking contrast to their 
traditional physiological role of oxygen transport. In fact, emerging evidence suggests that erythrocytes enhance 
functional coagulation properties and platelet aggregation. Among the spectrum of haematological abnormalities in 
diabetes, erythrocyte aggregation and decreased deformability of erythrocytes predominate. More importantly, they 
are implicated in the pathogenesis of microvascular complications of diabetes. The morphology of platelets, fibrin 
networks and erythrocytes are thus essential role players in unravelling the pathogenesis of cardiovascular complica-
tions in diabetic subjects.
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Background
The trend regarding the incidence of type 2 diabetes 
mellitus is that it is increasing in the general population 
because of increasing obesity and is likely to subsequently 
increase the incidence of coronary artery disease. It is 
also known that risk factors such as obesity, hypertension 
and hypercholesterolemia are crucial to the development 
of atherosclerosis which results in inflammation [1]. 
Fundamental to contributory factors of morbidity and 
mortality in diabetes is atherothrombotic complications 
[2]. Despite advances in antiplatelet therapies and con-
trol of modifiable risk factors; like hypertension, obesity, 
smoking and dyslipidaemia, the risk of ischaemic events 
remains high in patients with type 2 diabetes. There is 
thus a pressing need to understand the complexity of 
mechanisms contributing to atherothrombotic complica-
tions so that more effective therapies can be developed. 
Evidence shows that diabetes has been considered to be 
a prothrombotic status. Characteristic findings in type 
2 diabetes includes: increased coagulation, impaired 
fibrinolysis, endothelial dysfunction and platelet hyper-
reactivity [3].
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All stages in the pathophysiology of plaque formation 
with atherosclerosis are widespread and accelerated in 
type 2 diabetes. This is attributed to the imbalance in 
endothelial damage and repair mechanisms that are usu-
ally exhausted. The plaque is made up of erythrocytes, 
fibrin fibres and platelets [1]. Plaques are more suscepti-
ble to rupture and commonly referred to as “vulnerable 
plaque” syndrome. In particular, hyperglycaemia caus-
ing platelet activation, the increase in fibrinogen and 
hypofibrinolysis related to insulin resistance, all play a 
significant role in the development of angiopathy [4]. 
One research method that is used to study platelet struc-
ture and activation, is electron microscopy. This review 
defines ultrastructural findings in diabetic platelets, 
fibrin network and erythrocytes that can contribute to 
accelerated atherosclerosis. The outline of the review is 
highlighted in Fig. 1. The next paragraphs focus on struc-
ture and function of platelets, fibrin networks and eryth-
rocytes in relation to type 2 diabetes.
Review
Platelets
An important element postulated in the pathogenesis 
of the prothrombotic state in diabetic patients is plate-
let hyper-reactivity. The prothrombotic condition that is 
characteristic in diabetes, in turn, can be ascribed to the 
following factors: (1) increased coagulation, (2) impaired 
fibrinolysis, (3) endothelial dysfunction and (4) platelet 
hyper-reactivity [3, 5]. In diabetes, several mechanisms 
contribute to platelet dysfunction, such as those due to 
hyperglycaemia, insulin deficiency and insulin resist-
ance, associated metabolic conditions and other cellular 
mechanisms [6]. Even though platelets perform multiple 
functions, one of their primary functions is to respond to 
blood vessel injury by utilizing some of its unique char-
acteristic like changing shape, secreting granule con-
tents and aggregating to form a platelet clot. Secondary 
functions include: maintenance of vascular tone, inflam-
mation, host defence and tumour biology. Two major 
storage granules in platelets are α- and dense granules. 
Alpha-granules are most abundant and contain pro-
teins essential for platelet adhesion [7], while the dense 
granules function to recruit additional platelets to sites 
of vascular injury. Dense granules store molecules that 
are secreted upon platelet activation. Contents of dense 
granules include substances such as catecholamine, sero-
tonin, calcium, adenosine 5′-diphos-phate and adenosine 
5′-triphosphate [8].
Like with all cells, the plasma membrane lies beneath 
the outermost layer and its main component is a 
Fig. 1 Outline of the review: cells involved in coagulation are described with characteristics thereof which contribute to atherosclerosis. Ultras-
tructural findings in all 3 cell types are then reviewed (TF tissue factor, FVII factor VII, t-PA tissue plasminogen activator, PAI-I plasminogen activator 
inhibitor I).
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phospholipid bilayer in which cholesterol, glycolipids and 
glycoproteins are embedded. Unlike erythrocytes, plate-
lets present these molecules on their surface. The organi-
zation of the phospholipids between the inner and outer 
leaflets is asymmetrical and this regulates coagulation. 
There is an abundance of negatively charged phospho-
lipids in the inner leaflet of the plasma membrane which 
maintains the platelet surface in a non-procoagulant state 
[9]. The phospholipids contribute to coagulation by stim-
ulating the coagulation factor X to Xa and prothrombin 
to thrombin, both integral steps in the coagulation cas-
cade [10]. Other protein components of the resting plate-
lets include CD36, CD63, CD9 and GLUT-3 [7]. These 
are platelet activation markers and Eibl et al. found that 
subjects with type 2 diabetes exhibit increased expression 
of CD31, Cd36, Cd49b, CD62P and CD63 [11]. Research 
has shown that enhanced platelet activation, aggregation 
and increased expression of CD63 and CD62 contrib-
ute to atherosclerosis and thrombosis in diabetes [12]. A 
cross section of the discoid platelet also reveals that the 
platelet membrane is densely packed with highly specific 
surface receptors that tightly controls signal-dependent 
platelet activation and may modify α-granule release to 
coagulation, inflammation, atherosclerosis, antimicrobial 
host defence, angiogenesis, wound repair or malignancy 
[7].
Insulin resistance is a common finding in subjects with 
type 2 diabetes as are the complications in the macrovas-
cular and microvascular circulation. The insulin resist-
ance is responsible for numerous alterations both at the 
metabolic and cellular levels. Included in the target tis-
sues of insulin, in particular, the cellular systems that are 
affected is the endothelial cells, platelets, monocytes and 
erythrocytes [13]. Insulin’s action on platelets is to sensi-
tize platelets to the inhibitory effects of prostacyclin and 
nitric oxide on aggregation and to diminish the proag-
gregatory properties of agonists such as prostaglandin 
E1, and E2. During platelet aggregation and activation, 
mechanisms like phospholipase C-induced hydrolysis of 
inositol phospholipids and opening of ion channels are 
activated. This results in various physiological responses 
by inducing changes in the phosphorylation state, activity 
of enzymes and structural properties of key platelet pro-
teins [13].
Structural abnormalities found in diabetic platelets
Previous research has shown that diabetic platelets are 
characterised by increased adhesiveness and exagger-
ated aggregation. An array of mechanisms for the platelet 
hyper-reactivity has been postulated; decreased mem-
brane fluidity, altered platelet metabolism (impaired 
calcium and magnesium homeostasis), elevated gly-
coprotein receptors, increased thromboxane A2, 
non-enzymatic glycation of surface proteins, enhanced 
generation of reactive oxygen species and decreased anti-
oxidants with decreased prostacyclin and nitric oxide [2, 
14].
Our research team has looked at the ultrastructure 
of platelets and fibrin networks in diabetic patients and 
confirmed a changed platelet membrane ultrastructure 
[15]. In our studies, platelets seemed shrunken and the 
membranes showed blebbing [15]. Barely no pseudopo-
dia were seen, which normally develop spontaneously 
from platelets, as can be seen in control platelet. This 
blebbed morphology is typical of apoptosis as shown in 
Fig. 2d [15]. Due to the blebbed morphology, suggesting 
apoptosis, the integrity and surface of the platelet mem-
brane is impaired, implying functional impairment. The 
finding of membrane blebbing is critical as it may cause 
an increase in microparticles in diabetes. Microparticles 
are membrane-coated vesicles that originate by budding 
from their parental cells upon activation or apoptosis 
[16]. Cell-derived microparticles support coagulation and 
inflammation and they may be involved in accelerated 
atherosclerosis in diabetic patients [17].
Fibrin networks
There is an increased prevalence of atherothrombotic 
complications in subjects with diabetes. Prominent fea-
tures contributing to premature atherosclerosis in this 
group include: increased platelet reactivity and activa-
tion of coagulation factors with associated fibrinolysis 
[18]. During blood vessel injury, the normal physiologi-
cal response is that fibrin is deposited at the atheroscle-
rotic lesion. Thus the structure of the deposited fibrin 
has become significant and is viewed as a probable risk 
factor for increased affinity for cardiovascular events in 
subjects with atherosclerosis [19]. Investigating ultras-
tructural morphological changes in activated platelets, as 
well as that of fibrin networks, is emerging as an impor-
tant tool when studying different medical conditions. An 
aetiologic factor postulated to be causing ultrastructural 
changes in fibrin networks is abnormalities in the coagu-
lation process [20, 21].
The role of coagulation proteins in the coagulation cascade
The coagulation cascade includes both clot formation 
and fibrinolysis. Coagulation proteins play significant 
roles in both the processes. Diabetic subjects are known 
to have higher levels of circulating tissue factor (TF), 
FVII (factor VII), thrombin, fibrinogen, tPA (tissue plas-
minogen activator) and PAI-I (plasminogen activator 
inhibitor-I) [18]. TF initiates the thrombotic process with 
the ultimate production of thrombin which is crucial for 
the conversion of fibrinogen to fibrin. The increased TF 
levels in diabetes are under the control of both glucose 
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Fig. 2 SEM of platelets, fibrin networks and erythrocytes. a–c Taken from healthy individuals. d–f Taken from diabetic subjects. a Control plate-
let showing extended pseudopodia. b Major fibres and minor fibres of fibrin network, in a healthy control. c Erythrocyte of a healthy individual 
showing the typical morphology. d Diabetic platelets showing blebbed morphology. e Fibrin network of a diabetic subject showing dense matted 
deposits. f Diabetic erythrocyte entrapped in atypical fibrin fibres.
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and insulin. In fact, the two controlling factors tend to 
have an additive effect [22]. Another mechanism impli-
cated for the elevated TF levels is through the formation 
of advanced glycation end products and reactive oxygen 
species [23]. During the process of plaque rupture TF/
FVII complex is formed. Together with the underly-
ing platelet stimulation, this complex activates differ-
ent coagulation factors with the ultimate generation of 
thrombin [18]. Like TF, FVII is also elevated in subjects 
with diabetes and in those with the metabolic syndrome 
[5]. Early work has shown that FVII coagulant activity 
has been associated with fatal cardiovascular events and 
more importantly, increased FVII coagulant activity is 
directly correlated with raised blood glucose [18].
In both type 1 and type 2 diabetes thrombin genera-
tion is enhanced [22]. The hyper-glycaemia found in dia-
betic subjects, is the culprit causing increased thrombin 
production and when the hyperglycaemia is controlled, 
thrombin production is reduced, proving the prothrom-
botic nature of hyperglycaemia. [24] High concentration 
of thrombin results in altered clot structures as they are 
denser and less permeable making them more resistant to 
lysis [22]. Fibrinogen, the precursor of fibrin is described 
as an independent risk factor for cardiovascular disease 
and is often used as a surrogate marker for cardiovascu-
lar risk [25]. High fibrinogen levels are known to have a 
predictive value in the setting of silent myocardial ischae-
mia especially in subjects with type 2 diabetes [25].
Description of fibrin networks in diabetes
Diabetic subjects have been shown to have altered fibrin 
network structures as illustrated in Fig. 2e, and this was 
first confirmed by Jörneskog and colleagues [26]. Their 
findings indicated that plasma clots from Type 1 diabetes 
subjects have reduced permeability suggestive of a more 
compact structure which is independent of the presence 
of microvascular complications. Using confocal micros-
copy techniques, Alzahrani and colleagues found that 
clots made from pooled plasma-purified fibrinogen in 
diabetic and insulin resistant subjects have a more com-
pact fibrin network structure compared with controls, 
supporting earlier findings [18]. Figure  2b, e compares 
fibrin fibres of a healthy individual and that of a typical 
diabetic individual. Healthy fibrin fibres show individual 
fibres (Fig. 2b) while fibrin fibres in diabetes have thick-
ened masses of fibres with a netted morphology as indi-
cated Fig. 2e, giving the appearance of dense-matted net. 
This pattern is suggestive of a systemic inflammatory 
profile [15] and may contribute to the hypofibrinolysis 
which is a frequent and significant feature of diabetes.
Mechanisms involved in changing the fibrin network 
architecture in diabetes cause both quantitative and qual-
itative changes. Hyperglycaemia and insulin resistance 
induce qualitative changes as a result of increased glyca-
tion and oxidation while quantitative changes are associ-
ated with elevated levels of TF, thrombin, fibrinogen and 
PAI-1 as discussed above. The final end result is that the 
clot exhibits a denser structure and resistance to fibrinol-
ysis [18]. Clots formed at high fibrinogen concentrations 
show unique properties and includes: thin fibres, reduced 
pore size and increased tensile strength; also this clot is 
degraded at a lower rate by plasmin [27].
The first intervention trial by Pieters and co-workers, 
investigated the effect of glycaemic control on fibrin net-
work structures of type 2 diabetic subjects using isolated 
fibrinogen [28]. A variety of parameters were measured 
to highlight their findings and included, fibrinogen gly-
cation, clot permeability, turbidity measurements, fibre 
diameter, visco-elastic properties, lysis rate and effect 
of fibrinogen glycation on FXIIIa cross-linking. Results 
obtained were as follows:
  • Fibrinogen glycation: higher level of fibrinogen gly-
cation among the diabetic group with a significant 
decrease upon achieving glycaemic control.
  • Clot permeability: this parameter reflects the clot 
structure, specifically the average pore size. This was 
increased in the diabetic subjects and a significant 
correlation between permeability and HbA1c was 
also proven.
  • Turbidity measurements: analysis of this parameter 
results in turbidity curves which are used to charac-
terize the kinetics of polymerization and clot struc-
ture. The slope of increase in turbidity, representa-
tive of lateral aggregation was higher in the diabetic 
group.
  • Fibre diameter: this was measured using scanning 
electron microscopy (SEM), and the median fibre 
diameter of the clots from the diabetics and controls 
did not differ.
  • Viscoelastic properties: were similar between the 
controls and diabetics however, there was a lower 
proportion of inelastic component in the fibrin clots 
of the diabetic subjects.
  • Lysis rate: the diabetic subjects had a lower lysis rate.
  • Effect of fibrinogen glycation on FXIIIA cross-link-
ing: No differences were detected among the diabetic 
and control groups.
Subjects with diabetes have higher than normal tissue 
factor levels. Of significance is that tissue factor activity 
is controlled by both insulin and glucose. Another stimu-
lating factor for the synthesis of tissue factor particularly 
in diabetes is glycation end products and reactive oxygen 
species (ROS). Also the elevated production of throm-
bin in diabetic subjects has a direct effect on the clot 
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formation, structure and stability. The final product is 
thus a denser, less permeable clot which is more resistant 
to lysis. Linking the concept of diabetes as a prothrom-
botic state and inflammation is the elevated cytokine, 
IL-6 which stimulates the hepatocytes to produce more 
fibrinogen. Increased production of fibrinogen by hepat-
ocytes is also a common finding in insulin resistance [29].
Erythrocytes
It is no surprise that just like platelets and fibrin net-
works, erythrocytes have been shown to play a role in 
coagulation as well. This is in striking contrast to their 
traditional physiological role of oxygen transport. In fact, 
emerging evidence suggests that erythrocytes enhance 
functional coagulation properties and platelet aggrega-
tion [30]. Also, erythrocytes have been localized in coro-
nary atherosclerotic plaques [31]. Among the spectrum 
of haematological abnormalities in diabetes, erythrocyte 
aggregation and decreased deformability of erythrocytes 
feature strongly [32]. More importantly, they are impli-
cated in the pathogenesis of microvascular complica-
tions of diabetes. The adverse effects of glucose manifests 
in multiple ways: rearrangement of erythrocyte mem-
branes, defects in haemoglobin oxygen binding activity, 
alterations of mechanical features of the membrane and 
general aspects of the cell as well [33]. This is attributed 
to the prothrombotic nature of the erythrocytes as they 
increase blood viscosity and forcing platelets towards 
the vessel wall. Thus the integration of erythrocytes into 
a fibrin clot has an influence on clot structure and its 
mechanical properties [34–36].
Diabetic‑induced changes in the erythrocytes
Alterations in erythrocyte structure
In diabetic subjects the erythrocyte membrane becomes 
rigid and non-deformable. A decrease in the cholesterol 
to phospholipid ratio is responsible for this abnormal-
ity. Not only is the cholesterol component of the mem-
brane increased but there is a four-fold increase in the 
phospholipids concentration, which results in a signifi-
cant decreased ratio [37]. Of interest is that the propor-
tion of membrane cholesterol is increased and has been 
predicted to contribute to instability of atherosclerotic 
plaque [38, 39]. Cytoskeletal proteins, in particular, beta 
spectrin, ankyrin and protein 4.1 are heavily glycosylated 
[40]. Disturbances in ionic balance is attributed to the 
lowered Na+/K+—ATPase activity and this leads to com-
plications such as increased serum and intra-erythrocyte 
sodium and serum potassium in diabetic subjects. This 
also results in an increase in the cell size and increased 
osmotic fragility which contributes to the development 
of microvascular complications [41]. Elevated fibrino-
gen and glucagon are common findings in uncontrolled 
diabetes [42]. Oxidative stress plays a role in causing 
increased membrane lipid peroxidation and this may lead 
to abnormalities in composition and function. Enhanced 
levels of malondialdehyde (an indicator of lipid peroxida-
tion) [43] and reduced levels of glutathione and mem-
brane –SH group are features of the diabetic erythrocyte 
[44].
Despite absent mitochondria in the erythrocytes, they 
still depend on glucose as their energy source. How-
ever, in a hyperglycaemic environment, glycosylation of 
haemoglobin takes place which creates oxidative stress 
thereby making the cellular components of the eryth-
rocyte more vulnerable [45]. One of the functions of a 
membrane is to provide protection and this includes 
against oxidative damage as well. However, in diabetic 
subjects, lipid peroxidation causes structural damage 
to the membrane with a subsequent decrease in the cell 
deformability and fluidity. SEM and AFM findings in the 
study by Buys et  al., confirmed the correlation between 
the cytoskeletal protein and lipid layer damage with the 
ultrastructural roughness of the erythrocyte membrane 
found with AFM [46]. As mentioned previously, evidence 
points to glycosylation of cytoskeletal proteins and oxida-
tive damage of spectrin [47].
Alterations in erythrocyte aggregation and deformability
The property of aggregation is guided by the composition 
of erythrocyte membrane and plasma proteins fibrino-
gen and globulin. When fibrinogen levels are increased 
and albumin is decreased, aggregation is enhanced. A 
mechanism that favours increased tendency of eryth-
rocyte aggregation is the decreased ionic charge of the 
membrane. Microscopic examination of the erythrocyte 
aggregate reveals an increase in aggregate shape and 
size when compared to healthy controls. The parameter 
erythrocyte deformability unlike aggregation is modified 
by the composition of the membrane, cytoplasmic con-
tents and age of the erythrocytes [42]. It is the measure 
of the ability of the cells to deform under applied shear 
stress. [47] Advanced technological measurements 
confirm that in diabetes, deformability is significantly 
decreased. This abnormality is attributed to the specific 
changes in the membrane structure. The consequence 
of altered deformability is the increase in blood viscosity 
which can lead to increase in shear stress on the endothe-
lial wall [42]. Investigation of diabetic erythrocytes with 
cardiovascular complications is associated with lowered 
membrane fluidity when compared to healthy controls. 
The diffusion of protein and lipid molecules within the 
membrane is known as membrane fluidity and is depend-
ent on the presence of saturated and polyunsaturated 
fatty acid [48]. The increased tendency of erythrocyte 
from subjects with diabetes to adhere to cultured human 
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vascular endothelial cells was confirmed by research per-
formed by Wali et al. Their results suggest that a possible 
mechanism for the latter is a loss of lipid asymmetry and 
or less ordered packing in the outer leaflet of the diabetic 
erythrocyte membrane [49].
Diabetes, a multifactorial disease has a marked effect 
on the rheological and electrical properties of the eryth-
rocyte. The erythrocyte is commonly described as more 
rigid than normal with a reduced deformability. However 
diabetes also causes profound changes on the ultrastruc-
ture of erythrocytes, fibrin networks and platelets. Pre-
torius and co-workers showed a changed morphology in 
type 2 diabetic erythrocytes using the scanning electron 
microscope (SEM), which showed elongated cells form-
ing extended projections that twist around spontaneously 
formed fibrin fibres as indicated in Fig.  2f. The causa-
tive role of iron overload and subsequent non-enzymatic 
fibrinogen polymerization on altering the ultrastructure 
of erythrocytes in type 2 diabetes, has been detailed by 
Lipinski et al. [50, 51].
In the process of a thrombotic event many parameters 
(which are increased) play a role, however, increased lev-
els of fibrinogen feature strongly. This is of significance 
as it causes abnormal fibrin fibre formation visible as 
dense matted deposits (DMD) and the resulting coagu-
lum causes blood cells to change shape and to be trapped 
in the abnormal mesh [52]. An array of inflammatory dis-
eases, including type 2 diabetes mellitus are associated 
with increased fibrinogen levels and hypercoagulability 
which results in markedly changed fibrin morphology, 
DMDs [53]. DMDs may therefore reflect a hypercoagu-
lable profile. Of note is the close link between this hyper-
coagulability of fibrin and involvement of erythrocytes 
[54, 55]. Our research team has also shown that when 
fibrin clots abnormally, erythrocytes are entrapped more 
tightly inside the clot as indicated in Fig. 2f [51, 56]. The 
factors of both erythrocyte aggregation and fibrinogen 
interactions cause a changed viscosity which impacts on 
the optimal functioning of erythrocytes. It is thus diffi-
cult to ignore the influence of increased blood viscosity 
and increased fibrin concentration, not only in their role 
as strong predictors of cardiovascular diseases but also as 
important factors in the development of atherosclerosis 
[56–59].
Conclusion
Platelet dysfunction poses an increased risk for throm-
botic vascular events. The significance of platelet abnor-
malities in the atherothrombotic process has been 
highlighted by the use of antiplatelet drugs that form 
part of the therapeutic regime in reducing cardiovas-
cular risk [2]. The multifactorial aetiologies for platelet 
dysfunction is beyond the scope of this review, however, 
diabetes and the associated hyperglycaemia cannot be 
ignored. Hyperglycaemia induces a hypercoagulable 
condition and contributes to micro- and macrovascular 
disease. Studies have shown that optimal control of both 
fasting and post-prandial glucose levels will reduce the 
impact. It remains to see if the latter will improve mor-
phological findings of the platelet ultrastructure in dia-
betic subjects. Suppression of fibrinolysis and increased 
fibrinogen are among the group of haemostatic abnor-
malities in type 2 diabetes. Increased fibrinogen adds 
to the burden of cardiovascular risk by increasing blood 
viscosity, increasing the size of the clot, tissue deposition 
is increased and stimulation of atherosclerosis and vas-
cular thickening. Erythrocytes too contribute to the high 
incidence of atherosclerotic diseases in diabetes partly 
due to the association of abnormalities of erythrocyte 
composition and rheological function with increased 
oxidative stress.
The combination of blebbed platelets, abnormal fibrin 
in the form of dense matted deposits and changed eryth-
rocytes morphology creates a thrombotic risk cluster 
which underpins the development of cardiovascular 
disease. Analysis of ultrastructural findings in diabetic 
platelets, fibrin network and erythrocytes can reveal sig-
nificant findings which may add to a better understanding 
of the pathogenesis of atherosclerosis and thrombosis.
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